Manfred Eigen Campus, Essener Bogen 7
22419 Hamburg, de
+49 (40) 56081-242
Integrated Drug Discovery Alliance with Genentech
Evotec will apply its integrated and innovative drug discovery platform in combination with its extensive disease biology expertise against targets nominated by Genentech. This will include assay development and high throughput screening, medicinal chemistry and structural biology. The aim of the collaboration is to deliver high quality leads and development candidates to support Genentech's research efforts.
Further commercial details were not released.
Dr Werner Lanthaler, Chief Executive Officer of Evotec, commented: "We are proud that Genentech, one of the premier biopharmaceutical companies worldwide, has selected Evotec's scientists and innovative drug discovery platform to support their research efforts. We look forward to working closely with Genentech's scientists and achieving success together."
Founded more than 30 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines for patients with serious or lifethreatening medical conditions. The company, a wholly owned member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit www.gene.com.
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to email@example.com.